You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 5,389,530


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,389,530
Title: Methods for the production of antibodies and induction of immune responses to tumor-associated ganagliosides by immunization with gangloiside lactones
Abstract:The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.
Inventor(s): Hakomori; Sen-itiroh (Mercr Island, WA)
Assignee: The Biomembrane Institute (Seattle, WA)
Application Number:08/097,006
Patent Claims:1. A method for the production of antibodies to a tumor-associated ganglioside comprising:

(1) immunizing an animal with an immunogenic amount of a lactone of a tumor-associated ganglioside and a pharmaceutically acceptable carrier;

(2) isolating the immunized cells from said animal;

(3) fusing the isolated immunized cells with myeloma cells; and

(4) screening for hybridomas which produce antibodies having binding specificity to said ganglioside and collecting the antibodies so produced.

2. The method as claimed in claim 1, wherein said tumor-associated ganglioside is selected from the group consisting of GD.sub.3, GD.sub.2, sialyl Le.sup.a, sialyl Le.sup.X, sialyl difucosyl Le.sup.x, GM.sub.3, 6C ganglioside, G2 ganglioside, disialosyl Le.sup.a, monosialyl type 1 chain, disialosyl type 1 chain and fucosyl GM.sub.1.

3. The method as claimed in claim 1, wherein said immunogenic amount is about 2.0 to 5.0 .mu.g adsorbed on about 20 to 100 .mu.g of carrier.

4. The method as claimed in claim 1, wherein said pharmaceutically acceptable carrier is selected from the group consisting of Bacillus Calmette-Guerin (BCG), diptheria toxoid, and tetanus toxoid.

5. The method as claimed in claim 1, wherein said pharmaceutically acceptable carrier is selected from the group consisting of an artificial membrane a natural membrane and vaccinia virus.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.